Fludrocortisone acetate

CAS No. 514-36-3

Fludrocortisone acetate( 9α-fluoro Hydrocortisone Acetate | NSC 15186 | U 4845 )

Catalog No. M14781 CAS No. 514-36-3

Fludrocortisone Acetate is a synthetic mineralocorticoid, used to control the amount of sodium and fluids in your body.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
100MG 27 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fludrocortisone acetate
  • Note
    Research use only, not for human use.
  • Brief Description
    Fludrocortisone Acetate is a synthetic mineralocorticoid, used to control the amount of sodium and fluids in your body.
  • Description
    Fludrocortisone Acetate is a synthetic mineralocorticoid, used to control the amount of sodium and fluids in your body. It is used to treat Addison's disease by decreasing the amount of sodium that is lost (excreted) in your urine,also used to increase blood pressure.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    9α-fluoro Hydrocortisone Acetate | NSC 15186 | U 4845
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    514-36-3
  • Formula Weight
    422.5
  • Molecular Formula
    C23H31FO6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Pomalidomide-C6-COOH

    Pomalidomide-C6-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

  • Dehydrocorydaline (c...

    Dehydrocorydaline (chloride)

  • MRT-2359

    MRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.